NanoViricides closes $2M direct offering

The clinical-stage antiviral cause developer sold astir 1.3 cardinal shares of communal stock, oregon pre-funded warrants successful lieu of shares, on with accompanying warrants to acquisition an further astir 1.3 cardinal communal shares.

The offering was made to a azygous organization capitalist astatine a combined acquisition terms of $1.50 per stock and accompanying warrant.

The accompanying warrants transportation an workout terms of $1.75 per share. They volition go exercisable six months aft issuance and expire 3 years later.

NanoViricides said the offering generated aggregate gross proceeds of astir $2 cardinal anterior to deducting placement cause fees and different related expenses.

D. Boral Capital LLC served arsenic the exclusive placement cause for the transaction.

NanoViricides is processing broad-spectrum antiviral therapies utilizing its host-mimetic nanomedicine level technology.